<DOC>
	<DOCNO>NCT00787007</DOCNO>
	<brief_summary>The purpose study 1 ) test safety S-equol healthy volunteer 2 ) see quickly S-equol enters bloodstream , distribute body , broken remove , take food without food .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study S-Equol Healthy Volunteers</brief_title>
	<detailed_description>The study double blind , randomize , placebo-controlled , dose-escalation study safety tolerability single dose S-equol 320 mg healthy male female adult subject . Approximately 8 qualified volunteer select dose level randomly assign receive S-equol placebo , fast state . For 20 mg dose group , subject complete two treatment period , one fast state , one fed state . A safety review study result dose group occur Day 8 follow-up visit safety data available , prior enrollment/dosing next subsequent dose group . Given favorable safety review dose group 's experience , subsequent dose group enrolled/dosed least 10 day previous group 's dosing . Pharmacokinetic evaluation consist determination plasma urine concentration free total conjugate S-equol various time point . Safety evaluation include physical examination , vital sign , ECG , serum chemistry , hematology , urinalysis , 12-lead telemetry , assessment clinical sign symptom .</detailed_description>
	<mesh_term>Equol</mesh_term>
	<criteria>Healthy male female volunteer age 18 65 year , inclusive Female subject must nonpregnant nonlactating ; surgically sterile , postmenopausal use acceptable nonhormonal method birth control Must use hormonal agent device within 4 week prior enrollment In good health determine physician BMI 18 30 , inclusive Normal clinical laboratory test result Negative drug alcohol toxicology screen Negative HIV antibody hepatitis panel screen result For men 44 year age , PSA â‰¤ 2.0 ng/mL For woman 44 year age , normal mammography pelvic ultrasound Protein C Protein S activity level low limit normal Negative Factor V Leiden . History chronic , subacute acute condition clinical significance Total bilirubin level &gt; 0.9 , conjugate bilirubin &gt; 0.4 , unconjugated bilirubin &gt; 0.8 Fasting cholesterol level &gt; 280 mg/dL ; fast triglyceride level &gt; 1.5 x ULN History thromboembolic event estrogendependent benign malignant neoplasm Resting systolic blood pressure &gt; 140 mm Hg &lt; 90 mm Hg , diastolic blood pressure &gt; 90 mm Hg &lt; 60 mm Hg Resting pulse &gt; 100 beats/minute &lt; 45 beats/minute Abnormal 12lead ECG telemetry result Subject unwilling unable comply study rule History sudden cardiac death immediate family , personal history cardiac disease , treat hypertension , congestive heart failure , unexplained syncope History cancer , basal cell carcinoma stage 1 squamous cell carcinoma , successfully treat Use prescription overthecounter medication within 1 week prior Day 1 anticipates need medication course study History intolerance estrogen medication History substance abuse , drug addiction , alcoholism within 3 year Inability abstain alcohol , caffeine , Yerba mate tea , grapefruit , grapefruit juice flavonoidrich food 48 hour prior administration study medication throughout duration study . History smoking use tobacco nicotine contain product within 6 month Donated blood blood product within 30 day Mental instability inability compliant protocol Subject receive investigational test substance within 60 day anticipate receive investigational test substance Sequol course study Subject previously enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>